medigraphic.com

2006, Number S2

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2006; 44 (S2)

The substitution of blood transfusion versus the use of perfluorocarbons during cardiac surgery with cardiopulmonary bypass

Chávez NA, Verdín R, Rojas UM, Contreras F, Ferra R, Barroso J

Language: Spanish
References: 15
Page: 123-128
PDF size: 91.71 Kb.


ABSTRACT

Introduction: Open cardiac surgery requires the support of cardiopulmonary bypass (CPB), which requires more volume of blood transfusion. This condition increases the risk of infections and is sometimes unavailable.
Objective: to use an artificial oxygen carrier instead of blood transfusion during the open cardiac surgery with CPB, to reduce the use of transfusion.
Methods: 14 patients candidates for cardiac valve replacement received 5 mL/kg of perfluorocarbon (PFC) such as an artificial oxygen carrier during the cardiac surgery and were compared with 16 patients which received conventional blood transfusion.
Results: clinical and biochemical parameters did not show any significant differences between groups, however PaO2 in the PFC group increased with statistical significance during the cardiopulmonary bypass at 60 (300 vs 220 mmHg) and 120 minutes (280 vs 120 mmHg) as compared with the blood transfusion group.
Conclusions: PFC proved to be more efficient as an artificial oxygen carrier in open cardiac surgery (with CPB) and transfusion was not needed.


REFERENCES

  1. Chang TMS. Blood substitute based on modified hemoglobin prepared by encapsulation or crosslinking. Biomaterials, Artificial Cell and Immobilization Biotechnology 1992;20:154-174.

  2. Benesh R, Benesh RE, Yung S, Edalji R. Hemoglobin covalently bridged across the polyphosphate binding site. Biochem Biophys Res Com 1975;63:1123-1127.

  3. Chang TMS. Stabilization of enzyme by microencapsulation with concentrated protein solution or by crosslinking with glutaraldehyde. Biochem Biophys Res Com 1971;44:1531-1533.

  4. Jia L, Bonaventura J, Stamler JS, et al. Snitrosohemoglobin: A dynamic activity of blood involved in vascular control. Nature 1996; 380:221-226.

  5. Cabrales P, Tsai AG, Frangos JA, Briceńo JC, Intaglietta M. Oxygen delivery and consumption in the microcirculation after extreme hemodilution with perfluorocarbons. AJ Physiol Heart Circ Physiol 2004;287:H320-H330.

  6. Habler O, Kleen M, Messmer K. Clinical potential of intravenously administered perfluorocarbons. Acta Anaesthesiol Scan Suppl 1997;111:256-258.

  7. Hill SE, Faithfull NS, Flainm KE, Keipert PE, Newman F. Perflubron emulsion (AF0144) augment harvesting of autologous blood: A phase II study in cardiac surgery. J Card Vasc Anesth 2002;16:555-560.

  8. Sphan DR, van Brempt R, Theilmeier G, et al. Perflubron emulsion delays blood transfusion in orthopedic surgery. Anesthesiology 1999;91:1195-1208.

  9. Paxian M, Rensing H, Geckeis K, et al. Perflubron Emulsion in prolonged hemorrhagic shock. Anesthesiology 2003;98:1391-1399.

  10. Ivanitsky GR. Biophysics at the turn of the millennium: Perfluororcarbon media and gastransporting blood substitutes. Biophysics 2001;46:1-31.

  11. American College of Surgeons-Committee on Trauma: Shock, ATLS-Advanced Trauma Life Support for Doctors. Sixth Edition. Chicago: American College of Surgeons; 1997. p. 87-107.

  12. Spahn D, Waschke KF, Standl T, et al. Use of perflubron emulsion to decrease allogeneic blood transfusion in high-blood-loss non-cardiac surgery. Anesthesiology 2002;97:1338-1349.

  13. Spahn D, van Brempt R, Theilmeier G, et al. Perflubron emulsion delays blood transfusions in orthopedic surgery. Anesthesiology 1999;91:1195-1208.

  14. Cuignet OY, Baele PM, Van Obbergh LJ. A Secondgeneration blood substitute (Perflubron Emulsion) increase the blood solubility on modern volatile anesthetics. Anesth Analg 2002;95:368-372.

  15. Ide H, Kakiuchi T, Furuta N, Matsumoto H, Sudo K, Furuse A, et al. The effect of cardiopulmonary bypass on t cells and their subpopulation. Ann Thorac Surg 1987;44:277-282.




2020     |     www.medigraphic.com